Cargando…

NI-6 Preoperative differential diagnosis of grade II and grade III in cases with astrocytoma, IDH mutant

Purpose: We attempted to differentiate between IDH-mutant astrocytoma Grade II and grade III by using methionine (MET) positron emission tomography (PET) and magnetic resonance spectroscopy (MRS). Subjects and Methods: We retrospectively analyzed 41 adult supratentorial glioma cases with confirmed h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yano, Hirohito, Miwa, Kazuhiro, Nakayama, Noriyuki, Maruyama, Takashi, Ohe, Naoyuki, Ikuta, Souko, Ikegame, Yuka, Owashi, Etsuko, Ohmura, Kazufumi, Yokoyama, Kazutoshi, Kumagai, Morio, Muragaki, Yoshihiro, Iwama, Toru, Shinoda, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648256/ http://dx.doi.org/10.1093/noajnl/vdab159.069

Ejemplares similares

Differentiation of astrocytoma between grades II and III using a combination of methionine positron emission tomography and magnetic resonance spectroscopy
por: Yano, Hirohito, et al.
Publicado: (2023)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

NI-01 CONTRAST-ENHANCED MRI AND POSITRON EMISSION TOMOGRAPHY FOR DISTINGUISHING THE GRADE OF GLIOMA
por: Takei, Hiroaki, et al.
Publicado: (2019)

COT-30 Effect of tumor resection in 11C methionine accumulation area on survival in patients with glioblastoma
por: Ohmura, Kazufumi, et al.
Publicado: (2021)

NI-20 IS GLIOMATOSIS CEREBRI DIAGNOSED AS GRADEII IN NEUROIMAGING A POTENTIALLY GRADEII GLIOMA?
por: Owashi, Etsuko, et al.
Publicado: (2019)

Changes in Protein Level in the Cerebrospinal Fluid of a Patient with Cerebral Radiation Necrosis Treated with Bevacizumab
por: Yano, Hirohito, et al.
Publicado: (2014)

NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI
por: Yano, Hirohito, et al.
Publicado: (2019)

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
por: Yang, Xiefeng, et al.
Publicado: (2022)

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
por: Rautajoki, Kirsi J., et al.
Publicado: (2023)

Intraventricular glioneuronal tumor with disseminated lesions at diagnosis - a case report -
por: Yano, Hirohito, et al.
Publicado: (2011)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Naturopathic Treatment of Grade III Oligodendroglioma With Progression to Grade IV Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma and the Development of Spinal Gliomatosis
por: Terrani, Kristina F, et al.
Publicado: (2023)

ACT-26 PATTERN OF RECURRENCE IN NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH PHOTODYNAMIC THERAPY
por: Nakayama, Noriyuki, et al.
Publicado: (2022)

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
por: Weller, Jonathan, et al.
Publicado: (2022)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas
por: Marker, Daniel F., et al.
Publicado: (2020)

COT-05 Experience of fertility preservation in 3 male cases and 1 female case with high-grade glioma
por: Nakayama, Noriyuki, et al.
Publicado: (2020)

Mixed neuronal-glial tumor in the temporal lobe of an infant: a case report
por: Yano, Hirohito, et al.
Publicado: (2013)

Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas
por: Feraco, Paola, et al.
Publicado: (2020)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor
por: Zhao, Binghao, et al.
Publicado: (2022)

A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis
por: Geramizadeh, Bita, et al.
Publicado: (2021)

Prognostic stratification for IDH-wild-type lower-grade astrocytoma by Sanger sequencing and copy-number alteration analysis with MLPA
por: Makino, Yasuhide, et al.
Publicado: (2021)

Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas
por: Lasocki, Arian, et al.
Publicado: (2023)

MPC-04 Utility of comprehensive cancer genome analysis for brain tumors
por: Miwa, Kazuhiro, et al.
Publicado: (2020)

Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas
por: Mirchia, Kanish, et al.
Publicado: (2019)

Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant
por: Sohn, Beomseok, et al.
Publicado: (2021)

Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis
por: Stewart, James, et al.
Publicado: (2022)

Novel insight into histological and molecular astrocytoma, IDH‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors
por: Chen, Wenlin, et al.
Publicado: (2023)

Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma
por: Minniti, Giuseppe, et al.
Publicado: (2023)

Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
por: van Garderen, Karin A, et al.
Publicado: (2023)

Re-irradiation of recurrent glioblastoma multiforme using (11)C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy
por: Miwa, Kazuhiro, et al.
Publicado: (2014)

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma
por: van Lith, Sanne A. M., et al.
Publicado: (2016)

The Cancer Driver Genes IDH1 and IDH2 and CD204 in WHO-Grade 4 Astrocytoma: Crosstalk Between Cancer Metabolism and Tumour Associated Macrophage Recruitment in Tumour Microenvironment
por: Kurdi, Maher, et al.
Publicado: (2023)

Gene Expression Profiling in Human High-Grade Astrocytomas
por: Liu, Zhongyu, et al.
Publicado: (2011)

Transcriptional Analysis of Aggressiveness and Heterogeneity across Grades of Astrocytomas
por: Wang, Chunjing, et al.
Publicado: (2013)

Prognostic significance of multiple kallikreins in high-grade astrocytoma
por: Drucker, Kristen L., et al.
Publicado: (2015)

Low-Grade Astrocytoma Causing Dural and Calvarial Destruction
por: Belfquih, Hatim, et al.
Publicado: (2023)

Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification
por: Álvarez-Torres, María del Mar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_714lvds1b52s27p9q5vlm042qv